Effects of Murine-Derived Anti-Methamphetamine Monoclonal Antibodies on (+)-Methamphetamine Self-Administration in the Rat
- 1 June 2004
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 309 (3) , 1248-1255
- https://doi.org/10.1124/jpet.103.061762
Abstract
Two murine-derived anti-methamphetamine monoclonal antibodies were studied as potential pharmacokinetic antagonists of (+)-methamphetamine self-administration by rats. Intravenous administration of a 1 g/kg dose of the lower affinity [antibody equilibrium dissociation constant (Kd) = 250 nM] monoclonal antibody (mAb) designated mAb6H8, 1 day before the start of several daily 2-h self-administration sessions produced effects that depended on the dose of (+)-methamphetamine. mAb6H8 increased the rate of self-administration of a unit dose of 0.06 mg/kg (+)-methamphetamine, had little effect on the rate of self-administration of a unit dose of 0.03 mg/kg (+)methamphetamine, and lowered the rate of self-administration of a unit dose of 0.01 mg/kg (+)-methamphetamine to a level similar to that after saline substitution. mAb-induced changes in rates of self-administration occurred very early in self-administration sessions and lasted for 3 to 7 days. Intravenous administration of a 1 or a 0.6 g/kg dose of a higher affinity (Kd = 11 nM) mAb designated mAb6H4, 24 h before the first of several self-administration sessions, produced very similar effects to the lower affinity mAb, despite the more than 20-fold greater affinity for (+)-methamphetamine. It is proposed that these anti-methamphetamine antibodies bind some of the self-administered (+)-methamphetamine before it can penetrate into brain, thereby reducing the amount of free drug available to function as a reinforcer. Although neither of these mAb medications are optimal antibodies for treating (+)-methamphetamine abuse, the experiments demonstrate that anti-(+)-methamphetamine monoclonal antibodies can attenuate the self-administration of the drug and suggest the potential of using monoclonal antibodies as pharmacokinetic antagonists of (+)-methamphetamine.This publication has 23 references indexed in Scilit:
- USE OF ANTI-(+)-METHAMPHETAMINE MONOCLONAL ANTIBODY TO SIGNIFICANTLY ALTER (+)-METHAMPHETAMINE AND (+)-AMPHETAMINE DISPOSITION IN RATSDrug Metabolism and Disposition, 2003
- Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibodyBehavioural Pharmacology, 2002
- A Single Dose of Monoclonal Anti-Phencyclidine IgG Offers Long-Term Reductions in Phencyclidine Behavioral Effects in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2002
- A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: a dose and time course analysisInternational Immunopharmacology, 2001
- Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of ratsInternational Immunopharmacology, 2001
- A second-generation vaccine protects against the psychoactive effects of cocaineProceedings of the National Academy of Sciences, 2001
- Cocaine vaccines: Antibody protection against relapse in a rat modelProceedings of the National Academy of Sciences, 2000
- A Nicotine Conjugate Vaccine Reduces Nicotine Distribution to Brain and Attenuates Its Behavioral and Cardiovascular Effects in RatsPharmacology Biochemistry and Behavior, 2000
- A catalytic antibody against cocaine prevents cocaine’s reinforcing and toxic effects in ratsProceedings of the National Academy of Sciences, 1998
- Effects of passive immunization against morphine on heroin self-administrationPharmacology Biochemistry and Behavior, 1978